111 related articles for article (PubMed ID: 22290075)
1. 4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity.
Hudkins RL; Zulli AL; Dandu Rr; Tao M; Josef KA; Aimone LD; Haltiwanger RC; Huang Z; Lyons JA; Mathiasen JR; Raddatz R; Gruner JA
Bioorg Med Chem Lett; 2012 Feb; 22(4):1504-9. PubMed ID: 22290075
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationship of 5-pyridazin-3-one phenoxypiperidines as potent, selective histamine H(3) receptor inverse agonists.
Tao M; Aimone LD; Gruner JA; Mathiasen JR; Huang Z; Lyons J; Raddatz R; Hudkins RL
Bioorg Med Chem Lett; 2012 Jan; 22(2):1073-7. PubMed ID: 22197136
[TBL] [Abstract][Full Text] [Related]
3. Identification of pyridazin-3-one derivatives as potent, selective histamine H₃ receptor inverse agonists with robust wake activity.
Hudkins RL; Aimone LD; Bailey TR; Bendesky RJ; Dandu RR; Dunn D; Gruner JA; Josef KA; Lin YG; Lyons J; Marcy VR; Mathiasen JR; Sundar BG; Tao M; Zulli AL; Raddatz R; Bacon ER
Bioorg Med Chem Lett; 2011 Sep; 21(18):5493-7. PubMed ID: 21782432
[TBL] [Abstract][Full Text] [Related]
4. Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): histamine H(3) receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.
Hudkins RL; Josef KA; Becknell NC; Aimone LD; Lyons JA; Mathiasen JR; Gruner JA; Raddatz R
Bioorg Med Chem Lett; 2014 Mar; 24(5):1303-6. PubMed ID: 24513042
[TBL] [Abstract][Full Text] [Related]
5. 4,5-dihydropyridazin-3-one derivatives as histamine H₃ receptor inverse agonists.
Hudkins RL; Aimone LD; Dandu RR; Dunn D; Gruner JA; Huang Z; Josef KA; Lyons JA; Mathiasen JR; Tao M; Zulli AL; Raddatz R
Bioorg Med Chem Lett; 2012 Jan; 22(1):194-8. PubMed ID: 22142542
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists.
Becknell NC; Lyons JA; Aimone LD; Huang Z; Gruner JA; Raddatz R; Hudkins RL
Bioorg Med Chem; 2012 Jun; 20(12):3880-6. PubMed ID: 22578490
[TBL] [Abstract][Full Text] [Related]
7. 4-phenoxypiperidines: potent, conformationally restricted, non-imidazole histamine H3 antagonists.
Dvorak CA; Apodaca R; Barbier AJ; Berridge CW; Wilson SJ; Boggs JD; Xiao W; Lovenberg TW; Carruthers NI
J Med Chem; 2005 Mar; 48(6):2229-38. PubMed ID: 15771465
[TBL] [Abstract][Full Text] [Related]
8. 3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.
Hudkins RL; Becknell NC; Lyons JA; Aimone LD; Olsen M; Haltiwanger RC; Mathiasen JR; Raddatz R; Gruner JA
Eur J Med Chem; 2015 May; 95():349-56. PubMed ID: 25827402
[TBL] [Abstract][Full Text] [Related]
9. Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H₃ receptor antagonists with potent cognition enhancing activity.
Tao M; Aimone LD; Huang Z; Mathiasen J; Raddatz R; Lyons J; Hudkins RL
J Med Chem; 2012 Jan; 55(1):414-23. PubMed ID: 22107017
[TBL] [Abstract][Full Text] [Related]
10. Novel morpholine ketone analogs as potent histamine H3 receptor inverse agonists with wake activity.
Sundar BG; Bailey TR; Dunn D; Hostetler GA; Chatterjee S; Bacon ER; Yue C; Schweizer D; Aimone LD; Gruner JA; Lyons J; Raddatz R; Lesur B
Bioorg Med Chem Lett; 2012 Feb; 22(4):1546-9. PubMed ID: 22297111
[TBL] [Abstract][Full Text] [Related]
11. Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activity.
Covel JA; Santora VJ; Smith JM; Hayashi R; Gallardo C; Weinhouse MI; Ibarra JB; Schultz JA; Park DM; Estrada SA; Hofilena BJ; Pulley MD; Smith BM; Ren A; Suarez M; Frazer J; Edwards J; Hauser EK; Lorea J; Semple G; Grottick AJ
J Med Chem; 2009 Sep; 52(18):5603-11. PubMed ID: 19722526
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.
Tao M; Raddatz R; Aimone LD; Hudkins RL
Bioorg Med Chem Lett; 2011 Oct; 21(20):6126-30. PubMed ID: 21906941
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.
Richter HG; Freichel C; Huwyler J; Nakagawa T; Nettekoven M; Plancher JM; Raab S; Roche O; Schuler F; Taylor S; Ullmer C; Wiegand R
Bioorg Med Chem Lett; 2010 Oct; 20(19):5713-7. PubMed ID: 20801030
[TBL] [Abstract][Full Text] [Related]
14. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS
Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity.
Morini G; Comini M; Rivara M; Rivara S; Bordi F; Plazzi PV; Flammini L; Saccani F; Bertoni S; Ballabeni V; Barocelli E; Mor M
Bioorg Med Chem; 2008 Dec; 16(23):9911-24. PubMed ID: 18976927
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H
Nirogi R; Shinde A; Mohammed AR; Badange RK; Reballi V; Bandyala TR; Saraf SK; Bojja K; Manchineella S; Achanta PK; Kandukuri KK; Subramanian R; Benade V; Palacharla RC; Jayarajan P; Pandey S; Jasti V
J Med Chem; 2019 Feb; 62(3):1203-1217. PubMed ID: 30629436
[TBL] [Abstract][Full Text] [Related]
17. Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
Hudkins RL; Raddatz R; Tao M; Mathiasen JR; Aimone LD; Becknell NC; Prouty CP; Knutsen LJ; Yazdanian M; Moachon G; Ator MA; Mallamo JP; Marino MJ; Bacon ER; Williams M
J Med Chem; 2011 Jul; 54(13):4781-92. PubMed ID: 21634396
[TBL] [Abstract][Full Text] [Related]
18. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
Vaccaro WD; Sher R; Berlin M; Shih NY; Aslanian R; Schwerdt JH; McCormick KD; Piwinski JJ; West RE; Anthes JC; Williams SM; Wu RL; She HS; Rivelli MA; Mutter JC; Corboz MR; Hey JA; Favreau L
Bioorg Med Chem Lett; 2006 Jan; 16(2):395-9. PubMed ID: 16246552
[TBL] [Abstract][Full Text] [Related]
19. Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists.
Berlin M; Lee YJ; Boyce CW; Wang Y; Aslanian R; McCormick KD; Sorota S; Williams SM; West RE; Korfmacher W
Bioorg Med Chem Lett; 2010 Apr; 20(7):2359-64. PubMed ID: 20188550
[TBL] [Abstract][Full Text] [Related]
20. 3-(1'-Cyclobutylspiro[4H-1,3-benzodioxine-2,4'-piperidine]-6-yl)-5,5-dimethyl-1,4-dihydropyridazin-6-one (CEP-32215), a new wake-promoting histamine H3 antagonist/inverse agonist.
Hudkins RL; Gruner JA; Raddatz R; Mathiasen JR; Aimone LD; Marino MJ; Bacon ER; Williams M; Ator MA
Neuropharmacology; 2016 Jul; 106():37-45. PubMed ID: 26400408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
